MIRA-55 Moves Closer to IND as MIRA Completes Key Toxicology Studies
Key Points
- MIRA Pharmaceuticals completed seven-day dose-range finding toxicology and toxicokinetic studies of its oral, non-opioid inflammatory-pain candidate, MIRA-55, in rats and dogs.
- The studies were designed to assess tolerability, toxicity, and systemic drug exposure and to help select doses for the next stage of the company’s IND-enabling program.
- MIRA plans to advance into GLP-compliant toxicology work and is targeting a U.S. FDA Investigational New Drug application for MIRA-55 in the first quarter of 2027, subject to successful completion of remaining requirements.
- MIRA-55 remains preclinical and has not been approved by the FDA or any other regulatory authority.
MIRA Pharmaceuticals (Nasdaq: MIRA) has reported positive results from completed seven-day dose-range finding toxicology and toxicokinetic studies for MIRA-55, its investigational oral drug candidate for inflammatory pain.
The studies were conducted in rats and dogs and evaluated the compound’s tolerability, toxicology profile, and systemic exposure. According to MIRA, the work produced the cross-species data needed to guide dose selection for upcoming IND-enabling toxicology studies.
Studies Support Next Preclinical Step
Dose-range finding studies are an early part of drug development that help companies determine the dose levels to use in longer and more formal toxicology studies. MIRA said its completed work met that objective by generating information across two animal species to support the next phase of the MIRA-55 program.
The company plans to use the results to inform dose selection for Good Laboratory Practice, or GLP, toxicology studies. Those studies are generally required as part of an IND package before a drug developer can ask the FDA for clearance to begin clinical testing in humans.
MIRA is targeting an IND submission for MIRA-55 during the first quarter of 2027. That timeline depends on completing the remaining IND-enabling work, satisfying applicable regulatory requirements, and other development considerations.
Oral, Non-Opioid Pain Candidate
MIRA-55 is an oral small-molecule candidate being developed as a potential non-opioid treatment for chronic inflammatory pain. The company has described the compound as a next-generation cannabinoid analog intended to modulate cannabinoid-receptor activity while minimizing CB1-related psychoactive effects.
MIRA has previously reported preclinical inflammatory-pain data in which oral MIRA-55 normalized pain responses and reduced inflammation. The company said those effects were comparable to, or in later reporting exceeded, injected morphine in animal models. Those results are preclinical findings and cannot establish safety or effectiveness in humans.
Earlier Formulation Work Supports Development
The toxicology update follows formulation work announced in July, when MIRA said it selected a lead oral formulation after testing multiple versions of MIRA-55. The company reported favorable oral bioavailability, sustained systemic exposure, and reproducible distribution into brain and liver tissue in preclinical studies.
Together, the formulation, pharmacokinetic, and toxicology activities are intended to build the data package needed to move the program toward its planned IND filing.
Investor Perspective: Progress, But Still Preclinical
The new data represent a development milestone because they move MIRA-55 closer to formal IND-enabling studies and provide dose-selection information for that work. The planned first-quarter 2027 IND target will be the next major regulatory milestone for the program.
However, MIRA-55 is still at the preclinical stage. The company must complete additional toxicology, manufacturing, chemistry, and regulatory activities before submitting an IND, and the FDA must allow the IND to proceed before human trials can begin. Earlier efficacy and safety observations were generated in animal studies, meaning they may not translate to clinical outcomes in people.
